The other small molecule inhibitors of cancer targets include, e.g. the gefitinib - inhibitor of epidermal growth factor receptor (EGFR) kinase and erlotinib- the inhibitor of EGFR in non small cell lung cancer (NSCLC) patients; the lapatinib- inhibitor of EGFR/ERBB2 for ERBB2-positive breast cancer; and the sorafenib- inhibitor of vascular epidermal growth factor receptor (VEGFR) kinase, in renal cancer [47]. The gene discussed is ERBB2; the disease is renal carcinoma.